Target Thyroid Levels in Pregnancy
For hypothyroidism in pregnancy, target TSH <2.5 mIU/L in the first trimester and <3.0 mIU/L in the second and third trimesters; for hyperthyroidism, maintain free T4 at or just above the upper limit of the nonpregnant reference range. 1
Hypothyroidism Targets
TSH Goals by Trimester
- First trimester: TSH <2.5 mIU/L
- Second trimester: TSH <3.0 mIU/L
- Third trimester: TSH <3.0 mIU/L
These targets are critical because overt maternal hypothyroidism causes serious adverse fetal effects including premature birth, low birth weight, respiratory distress, and impaired neurodevelopment 1. Even TSH levels in the upper normal range increase fetal loss compared to lower normal levels 1.
Preconception Planning
If hypothyroidism is diagnosed before pregnancy, adjust levothyroxine dose preconception to achieve TSH ≤2.5 mIU/L 1. This prevents the need for rapid dose escalation in early pregnancy when fetal brain development is most vulnerable.
Dose Adjustments During Pregnancy
Levothyroxine requirements increase by 30% or more starting at 4-6 weeks gestation 1. Women on thyroid replacement should increase their dose immediately upon pregnancy confirmation—typically by taking an extra 2 doses per week as a practical starting point.
Monitor thyroid function:
- Recheck TSH within 30-40 days after any dose change
- Then every 4-6 weeks throughout pregnancy 1
- After delivery, decrease back to prepregnancy dose 1
Subclinical Hypothyroidism
Treat subclinical hypothyroidism (elevated TSH with normal free T4) with levothyroxine, particularly in TPO antibody-positive women, as treatment improves obstetrical outcomes 1. While neurological benefit to offspring remains unproven, the potential benefits outweigh minimal risks.
Hyperthyroidism Targets
Free T4 Goals
Maintain maternal free T4 at or just above the upper limit of the nonpregnant reference range 1. Alternatively, maintain total T4 at 1.5 times the upper limit of normal. This approach minimizes fetal exposure to antithyroid drugs while preventing maternal thyrotoxicosis.
Antithyroid Drug Selection
- First trimester: Use propylthiouracil (PTU) due to methimazole's association with congenital abnormalities during organogenesis 1
- Second and third trimesters: Consider switching to methimazole to reduce maternal hepatotoxicity risk from PTU 2
Distinguishing Gestational Thyrotoxicosis
Differentiate Graves' disease from gestational thyrotoxicosis (which requires no treatment) by checking for:
- TSH receptor antibodies (TRAb) - positive in Graves'
- Clinical signs of autoimmunity
- Typical goiter 1
Gestational thyrotoxicosis is self-limited and related to hCG stimulation; most patients need only symptomatic management with beta-blockers if severely symptomatic 3.
Laboratory Interpretation Caveats
Use trimester-specific reference ranges for TSH, as standard nonpregnant ranges lead to misdiagnosis 1. If your laboratory lacks pregnancy-specific ranges:
- For total T4: multiply nonpregnant range (5-12 mg/dL) by 1.5-fold in second and third trimesters 1
- Free T4 assays are unreliable in pregnancy; free T4 index ("adjusted T4") is more reliable 1
Recent data from 2025 shows that locally-derived reference ranges differ from ATA recommendations and affect diagnosis rates 4. When possible, use manufacturer- and gestation-specific ranges 5.
High-Risk Monitoring
Women with thyroid autoimmunity who are euthyroid at pregnancy onset remain at risk for developing hypothyroidism. Monitor TSH every 4-6 weeks throughout pregnancy in these patients 1.
The evidence base for these recommendations comes primarily from the 2012 Endocrine Society guidelines 1, which represent the most comprehensive guideline-level evidence available, though newer 2026 ATA guidelines 6 are now emerging to update these standards.